Wall Street Zen Upgrades Enliven Therapeutics (NASDAQ:ELVN) to Hold

Key Points

• Wall Street Zen upgraded Enliven Therapeutics from “sell” to “hold.” Overall analyst sentiment remains more positive, with a “Moderate Buy” consensus from 10 Buy and two Sell ratings and an average price target of $75.44.
• Enliven reported quarterly earnings per share of -$0.36, beating analysts’ estimate of -$0.45; analysts expect full-year EPS of -$1.79.
• The stock opened at $49.43, within its 52-week range of $14.78 to $62.32. Company insiders sold 31,054 shares worth about $1.49 million over the last quarter.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) was upgraded by Wall Street Zen from a "sell" rating to a "hold" rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other brokerages also recently commented on ELVN. Mizuho upped their target price on Enliven Therapeutics from $62.00 to $73.00 and gave the company an "outperform" rating in a report on Tuesday, August 18th. Barclays began coverage on Enliven Therapeutics in a research note on Tuesday, August 18th. They issued an "overweight" rating and a $78.00 price objective on the stock. JPMorgan Chase & Co. started coverage on shares of Enliven Therapeutics in a research note on Thursday, October 1st. They issued an "overweight" rating and a $75.00 target price for the company. Guggenheim reaffirmed a "buy" rating and set a $78.00 price objective on shares of Enliven Therapeutics in a research note on Friday. Finally, HC Wainwright lifted their price objective on Enliven Therapeutics from $65.00 to $73.00 and gave the stock a "buy" rating in a report on Monday, October 19th. Ten equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $75.44.

Enliven Therapeutics Price Performance

NASDAQ:ELVN opened at $49.43 on Friday. Enliven Therapeutics has a one year low of $14.78 and a one year high of $62.32. The business has a fifty day moving average price of $47.25 and a 200-day moving average price of $43.08. The firm has a market capitalization of $3.62 billion, a price-to-earnings ratio of -28.91 and a beta of 0.34.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.09. On average, equities research analysts expect that Enliven Therapeutics will post -1.79 earnings per share for the current fiscal year.

Insider Transactions at Enliven Therapeutics

In other Enliven Therapeutics news, CFO Benjamin Hohl sold 6,018 shares of the business's stock in a transaction on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the transaction, the chief financial officer owned 38,000 shares of the company's stock, valued at approximately $1,462,240. The trade was a 13.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $46.67, for a total transaction of $606,710.00. Following the transaction, the director directly owned 13,000 shares of the company's stock, valued at approximately $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 31,054 shares of company stock worth $1,493,823 over the last quarter. 3.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in Enliven Therapeutics during the 1st quarter worth about $38,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Enliven Therapeutics during the 3rd quarter valued at about $53,000. Sterling Capital Management LLC increased its position in shares of Enliven Therapeutics by 1,180.7% in the third quarter. Sterling Capital Management LLC now owns 1,921 shares of the company's stock valued at $88,000 after acquiring an additional 1,771 shares during the last quarter. State of Wyoming bought a new stake in shares of Enliven Therapeutics during the 2nd quarter worth about $96,000. Finally, ProShare Advisors LLC lifted its position in Enliven Therapeutics by 29.5% during the third quarter. ProShare Advisors LLC now owns 9,852 shares of the company's stock worth $452,000 after purchasing an additional 2,246 shares during the period. 95.08% of the stock is currently owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.